Laman UtamaADAP • NASDAQ
add
Adaptimmune Therapeutics PLC - ADR
Tutup sebelumnya
$0.59
Julat hari
$0.57 - $0.61
Julat tahun
$0.53 - $2.05
Permodalan pasaran
147.97J USD
Bilangan Purata
2.24J
Pertukaran utama
NASDAQ
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (USD) | Sep 2024info | Perubahan T/T |
|---|---|---|
Hasil | 40.90J | 458.83% |
Perbelanjaan pengendalian | 21.28J | 31.63% |
Pendapatan bersih | -17.62J | 61.37% |
Margin untung bersih | -43.07 | 93.09% |
Pendapatan bagi setiap syer | -0.01 | 70.15% |
EBITDA | -11.86J | 72.88% |
Kadar cukai berkesan | -4.95% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (USD) | Sep 2024info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 186.09J | 15.06% |
Jumlah aset | 317.44J | 7.01% |
Jumlah liabiliti | 237.45J | 13.88% |
Jumlah ekuiti | 79.99J | — |
Syer tertunggak | 255.88J | — |
Harga kepada buku | 1.91 | — |
Pulangan pada aset | -11.48% | — |
Pulangan pada modal | -24.62% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (USD) | Sep 2024info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | -17.62J | 61.37% |
Tunai daripada operasi | -54.45J | -20.58% |
Tunai daripada pelaburan | -66.02J | -215.20% |
Tunai daripada pembiayaan | 25.00J | 4,094.80% |
Perubahan bersih dalam tunai | -95.25J | -840.01% |
Aliran tunai bebas | -41.07J | -62.70% |
Perihal
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park. In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. Wikipedia
Diasaskan
2008
Tapak web
Pekerja
449
